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The year 1996 saw the John and Dorothy Morgan Cancer Center at Lehigh Valley
Hospital (LVH) take several more steps towards fulfilling its vision of becoming the
resource for cancer care in the region. After 26 years in upstate New York at Albany
Medical College as medical student, house officer, fellow and faculty, I joined the center
with a profound sense of stewardship as the first full-time director of this growing
cancer program.
The very existence of the Morgan Cancer Center demonstrated to me the progress
already made by the leadership of Lehigh Valley Hospital and Health Network
(LVHHN) toward the goal of improved cancer control in the
Lehigh Valley. Envisioned and created by the community, it is
a cancer center for the community. My own strong sense of
stewardship for this vision has resulted in a cancer center mission
grounded in the fundamental principles of cancer control:
establishing community-based services aimed at cancer prevention;
access to state of art diagnostic, evaluation and treatment services;
and the provision of support and rehabilitation opportunities for
patients and families affected by malignant diseases and blood disorders.
This comprehensive cancer control mission is supported by patient care
services, a commitment to both professional and public cancer education,
the advancement of cancer treatment through clinical investigation and a
commitment to developing partnerships with the academies at Penn State
University's College of Medicine and Johns Hopkins Oncology Center, as
well as our neighboring health care providers in the Lehigh Valley and our
colleagues in PennCAREsM.
In 1996 we furthered that commitment by implementing additional
high-tech treatment capabilities in radiation oncology, establishing a center for Gregory Harper, M.D.
Directorpain management and laying the foundation for a new, patient-centered breast
health service aimed at easing the journey of women faced with breast cancer.
Moreover, the genesis of other advancements took hold: a hematopoietic stem
cell transplant program, the renovation of an inpatient center for cancer and blood
disorders, and the growth of new cancer specialties in gynecologic oncology, surgical
oncology, and head and neck oncology.
Since joining the LVHHN team, I have enlisted the help of key colleagues to
develop the cancer center mission and a new structure to support it. As Associate
Director for Research, Herbert C. Hoover, Jr., M.D., will direct our overall clinical
research mission. After 25 years of providing leadership for clinical oncology research at
LVH, David Prager, M.D., has resigned his posts with the National Surgical Adjuvant
Breast and Bowel Project (NSABP) and the Eastern Cooperative Oncology Group
(ECOG) but will remain active in the groups and will continue to participate in the
clinical trials mission. Dr. Hoover has been named the NSABP principal investigator for
THE MORGAN CANCER CENTER
ENVISIONED AND CREATED
BY THE COMMUNITY,
IS A CANCER CENTER
FOR THE COMMUNITY.
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Mark Young, M.D., will serve as the Associate Director of Cancer
Control, a role complemented by his duties as the Leonard Parker Pool
Chair of Community Health and Health Studies at LVH. Working
through the Center for Health Promotion and Disease Prevention, as well
as the Coalition for a Smoke Free Valley, Dr. Young is committed to decreasing the
impact that smoking and tobacco products have on the most common cause of cancer
death among both men and women - lung cancer. In addition, research on cancer
prevention behaviors will be conducted by MESH - a new program of the Community
Health and Health Studies department that seeks to Measurably Enhance the Status of
Health in the Lehigh Valley community. Results from a risk factor survey, developed by
the Centers for Disease Control, will enable MESH and the cancer center to develop
intervention programs where needed.
Robert Riether, M.D., Chairman, and Dennis Giangiulio, M.D., Vice Chairman of
the Cancer Committee will serve as the principal medical staff liaisons to the Morgan
Cancer Center and have the responsibility of ensuring LVH maintains its accreditation
as a teaching hospital for the American College of Surgeon's Commission on Cancer.
In addition, Dr. Riether and I have created an enriched interdisciplinary approach to
cancer disease management through the development of disease management groups
who will oversee the design and implementation of cancer care guidelines and who will
monitor both adherence to established guidelines and also review costs and clinical
outcomes of cancer services provided at LVH.
Significant challenges and opportunities have emerged as the Morgan Cancer
Center moves into another year. Central to these is the continued evolution of the
cancer center's core mission of community-based cancer control. It is a privilege for
me to direct the activities associated with the cancer center and I'm excited about the
possibilities facing us as we work on behalf of our community to reduce the burden of
cancer borne by the patients and families of the Lehigh Valley.
617t2~
Gregory R. Harper, M.D., Ph.D.
Director,John and Dorothy Morgan Cancer Center
Lehigh ValleyHospital and Health Network
LVH and I will serve as senior investigator of the ECOG. Moreover, Dr.
Hoover is in the forefront of developing effective tumor vaccines for the
treatment of colorectal cancer and is director of the tumor biology and
vaccine laboratory at LVH.
In addition to establishing membership in the Radiation Therapy
Oncology Group to enhance our clinical research mission, Victor Risch,
M.D., Ph.D., will lead the cancer center's education mission as Associate
Director for Cancer Education. Having nurtured our multidisciplinary
cancer treatment conferences, Dr. Risch is well suited to develop our
continuing medical education program and to work with LVH's Center for
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Overview
The John and Dorothy Morgan Cancer
Center of Lehigh Valley Hospital (LVH) is among
the nation's most advanced ambulatory cancer
treatment facilities. It was created to accommodate
the needs of cancer patients and their medical
providers under one roof to ensure a multidisci-
plinary approach by physicians and other health
professionals.
Designed with extensive input from patients,
the center opened in late 1993 and grew to handle
more than 1,500 analytical cases annually. It offers
chemotherapy treatment areas, radiation therapy
rooms, a dedicated pharmacy, patient and profes-
sionallibraries, conference rooms, classrooms,
private meeting areas and an American Cancer
Society resource room. Advanced treatment
technologies include stereotactic radiosurgery, high
dose rate brachytherapy and three-dimensional,
computerized treatment planning.
The center's affiliation with John Hopkins
Oncology Center gives patients access to clinical
trials and resources that explore and provide the
latest treatment approaches.
Additionally, the center has developed a unique
approach to conducting
cancer conferences orDisease Oriented Programs
BREAST tumor boards. Instead
of conducting a retro-
spective review of a




















guidance of the CancerUROLOGIC
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Committee, six specialty tumor boards are
conducted each month on a weekly, biweekly or
monthly basis: colon/rectal, breast, pulmonary,
urology, neurology and gynecologic oncology. In
addition, a weekly general tumor board is held,
during which malignancies of special interest,
recurrent and metastatic tumors and cancers of
other organ sites are discussed.
A similar format is followed for each
conference and it is this format that is unique to
LVH. Physicians present a significant patient
history, up to and including the cancer diagnosis.
The multidisciplinary team in attendance then
reviews in detail the radiographic, cytologic and
histologic studies of the case, discusses potential
treatment options, and compares those options to
established patient management guidelines. Each
patient also is reviewed for eligibility in a clinical
trial. The team then recommends a treatment plan,
based on the stage of the patient's disease, medical,
and psychological history.
After the conference, a letter detailing
treatment recommendations and clinical trial eligi-
bility, as well as a copy of the clinical trial, is sent to
the treating physician. Follow up is conducted to
determine how tumor board recommendations were
used by the treating physician and if established
guidelines for care were followed.
In 1996, physicians presented 1,015 cases at
208 tumor boards with participation from 6,177
health care professionals from a variety of oncologic
and related disciplines, of whom 3,800 were physi-
cians. Of the cases presented, nearly 75 percent
were presented prior to having completed a defin-
itive course of treatment; hence, discussion at tumor
board and the development of recommendations
were helpful to the physician and patient in
planning a full course of treatment.
To further enhance the care recommended and
provided to patients, the Morgan Cancer Center
undertook a reorganization in 1996 to form Disease
Management Programs. The main responsibility of
each program is to develop appropriate guidelines
and clinical pathways for the screening, early
detection, diagnosis, treatment, and rehabilitation of
patients with cancer, building upon previously
developed management guidelines. Support for this
initiative, as well as outcome analysis, is provided
by the Oncology Clinical Indicators Program.
In 1995 and 1996, management guidelines were
developed, approved and implemented for treating
colon/rectal, lung, prostate and breast cancers. The
process of guideline implementation and confor-
mance monitoring is greatly facilitated by the
information available through the Morgan Cancer
Center Tumor Registry, which has a data base of
16,275 analytic cases. The Tumor Registry actively
follows nearly 9,000 cases and maintains an average
lost to follow rate of 6 percent.
Performance evaluations of the management
guidelines began for breast cancer in 1996 with
monitoring of the other areas to follow in 1997.
While the evaluation noted a high rate of guideline
conformance, it also identified two areas of
variance. Interventions were formulated and
the compliance rate increased.
Further coordination of breast cancer care
occurred when the Morgan Cancer Center laid
the foundation for a new Breast Health Services
Program. The new approach was designed, with
the counsel of patients and physicians, to enhance,
expand and integrate existing breast screening and
diagnostic programs with the convenience of
multiple locations. The comprehensive program
provides education, risk assessment, second opinion,
treatment planning (mammography, ultrasound
and stereotactic biopsy), access to oncologic
consultation and clinical trials, psychosocial
support and community outreach through a
multidisciplinary approach.
Education
VICTOR RISCH, M.D., PH.D., ASSOCIATE DIRECTOR
The Morgan Cancer Center devotes many
resources to educational programs for professionals,
patients and the community.
Key professional education programs in 1996
included: Oncology Core Course, Chemotherapy
Course, Radiation Oncology Annual Conference
and Current Trends in Cancer Care Annual
Conference. Special lectures included: Esophageal
Cancer, Lung Cancer, Chemotherapy for Pancreatic
Cancer, Nutritional Needs of the Oncology Patient,
Talking With the Terminally Ill, and reviews of
various treatment agents.
Key patient and community education activities
during 1996 included expanding the patient library,
conducting certification training in breast self-
examination and giving a "Genetics in Cancer"
lecture. The Morgan Cancer Center also hosted a
Breast Cancer Awareness Day open house featuring
I
lectures and breast self-examination demonstrations,
a "Careers in Oncology" evening, and a "Looking
for Laughter" program for cancer survivors.
Future goals for the Education Division include
increasing input into residency training programs
and redesigning the nursing education curriculum.
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Research
HERBERT C. HOOVER, JR., M.D., ASSOCIATE DIRECTOR
The Clinical Trials Office
supports the development of
and participation in cooper-
ative group treatment and
prevention trials, as well as
industry-sponsored studies.
The staff is responsible for
monitoring compliance with
Cooperative Oncology Group
and industry requirements for IRB approvals for all
trials available at LVH.
To ensure a cancer patient's access to the most
appropriate care, the Clinical Trials Office encourages
participation in clinical trials by reviewing the eligi-
bility of all patients presented at cancer conferences
and providing feedback to the treating physician.
During 1996, Morgan Cancer Center enrolled
49 patients in clinical research studies. Of those, 18
entered an Eastern Cooperative Oncology Group
trial, seven participated in a National Surgical
Adjuvant Breast and Bowel Project, four enrolled
in an industry-sponsored study and two entered
the Breast Prevention Clinical Trial.
Morgan Cancer Center also enrolled 18
patients in an epidemiologic study done in
conjunction with the University of Pennsylvania
Medical Center. The study evaluates the
relationship between long-term combination oral
contraceptive use and the subsequent development
of epithelial ovarian cancer. Additionally, this study
will allow the efficient evaluation of other possible
risk factors for ovarian cancer.
Cancer Control
MARK YOUNG, M.D., ASSOCIATE DIRECTOR
••
Cancer Control is charged with developing
effective community education and outreach
strategies in collaboration with physicians to
promote public awareness of cancer prevention and
early detection to reduce the burden of cancer
among the under served populations. Annual activ-
ities include a skin cancer screening program in
conjunction with the American Academy of
Dermatology during National Skin Cancer
Awareness Month in May and a prostate cancer
awareness program during National Prostate
Cancer Awareness Week in September.
Of the 157 people who participated in the
1996 skin cancer screening, 16 cancers were
detected. A total of 2,183 people have been
screened since the program began in 1989.
Two early cancers were detected during the
1996 prostate screening in which 236 men partic-
ipated. A total of 3,481 men have participated in the
program since it began in 1990.
6
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The cancer center also sponsors Cancer
Answers, a hospital-based information hotline for
referring physicians to recommend to their patients.
The line, staffed by an oncology nurse, offers infor-
mation to the general public on subjects ranging
from second opinion referrals to warning signs and
general cancer awareness information. Cancer
Answers assisted more than 2,000 callers in 1996.
Clinical Services
Medical and Surgical Oncology
Medical oncology at LVH provides a full range
of neo-adjuvant, adjuvant and palliative systemic
therapies for solid tumors and hematologic
neoplasms. When a surgical approach is necessary,
current techniques include laser, free-flap and
reconstructive, laparoscopic, and stereotactic biopsy
and radiosurgeries.
Plans for a comprehensive hematopoietic stem
cell transplant program took form in 1996 with
renovations of the inpatient facility, construction
of a processing laboratory and development of
ambulatory services. The construction of a Biological
Therapy Center also began in 1996. The center will




This clinical service is staffed by 13 oncology-
certified nurses and includes an inpatient unit,
outpatient infusion area and physicians' clinical
offices. Clinical specialists also contribute to patient
education and support activities. In 1996, oncology
nursing developed an infrastructure to support the
integration of leadership, services and educational
activities across the continuum of care. The outpa-
tient infusion area also expanded its autologous
blood collection for preoperative patients to include
LVH's downtown location. In addition, the infusion
area continues to provide outpatient chemotherapy,
intravenous infusions, bloodlblood product transfu-
sions and medication administration.
Psychosocial Support
Morgan Cancer Center provided clinical
support services for more than 15,000 people in
1996. These include behavioral and counseling
services, cancer support teams, support groups and
survivorship activities for people with cancer and
their families.
In addition to the more traditional psychother-
apeutic interventions, the cancer support team -
v
made up of an oncology nurse, oncology social
worker and former patient - provides emotional
support, education, information and coordination of
care with other hospital and community services.
The Morgan Cancer Center staff facilitates a
number of support groups involving adult and
adolescent patients, family members and friends,
and long-term survivors. Discussion topics focus on
cancer treatments, day-to-day living experiences,
advocacy and bereavement.
The Morgan Cancer Center is one of four
contractors in Pennsylvania that has implemented
the Family Caregiver Cancer Education Program.
The program focuses on meeting the needs of
family and friend caregivers, and patients in the
home care setting throughout a 17 county area.
Staff activities include conducting local instructor
and family caregiver courses, distributing a state-
published manual, "Helping People Cope: A Guide
For Families Facing Cancer," and maintaining the
toll-free information line, 1-800-PA-CANCER.
In response to the rapidly increasing Latino
population, a Spanish version of the Family
Caregiver Education Program was implemented
during 1996. The program reached nearly 5,700
people in 1996 and was responsible for distributing
more than 25,000 pieces of cancer-related literature.
Pain Management
The Center for Pain Management underwent a
physical redesign in 1996 to accommodate its
growing patient population and expanded service.
The center focuses on the evaluation and treatment
of patients with chronic pain. Various modalities
employed to treat pain include: medication
management, anesthetic nerve blocks, epidural
steroid injections, bio-feedback and relaxation
therapy, acupuncture, spinal cord stimulation, nutri-
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Radiation Oncology
LVH's radiation oncology department provides
external beam radiation therapy (teletherapy) using
advanced linear accelerator technology. The
equipment represents some of the most powerful
units delivering radiation therapy on the East Coast.
Comprehensive brachytherapy services also are
available and in 1996 were expanded to include a
remote high dose rate (HDR) brachytherapy unit.
HDR has dramatically altered the way
brachytherapy is delivered, from a three-day,
inpatient procedure to an outpatient procedure.
Also in 1996, the radiation oncology
department began using a three-dimensional,
computerized treatment planning system. This
allows for the outline of critical structures in all
dimensions, thus protecting healthy tissues from
receiving high doses of radiation and, as a result,
decreasing treatment morbidity. Use of this
technology is expanding, with about 60 percent of




The department also provides stereotactic
radiosurgery treatment using technology to treat
lesions with an accuracy of +/- 0.2 mm in three-
dimensional space. Stereotactic radiosurgery treat-
ments are routinely delivered to patients with
otherwise inoperable primary and metastatic lesions
within the brain, as well as to patients with benign
conditions, such as benign brain tumors or anterior
venous malformations. A team consisting of a
radiation oncologist, radiation physicist and neuro-
surgeon administer a high precision beam of
radiation in a single outpatient treatment session.
LVH is the only hospital in the region offering this
procedure .
Rehabilitation
The effects of cancer and its treatment have
short- and long-term implications. As such, the
main emphasis of rehabilitative services at Morgan
Cancer Center is to positively impact a patient's
ability to function in a normal role at home and in
the community.
Home Care and Hospice
Lehigh Valley Home Care and Lehigh Valley
Hospice are integral parts of the continuum of care
provided to cancer patients. Providing nearly
200,000 visits annually, Lehigh Valley Home Care is
one of the largest regional hospital-based home care
programs in the state. Cancer Care, a specialized
program offered by Home Care, is designed for
patients undergoing curative treatments.
Lehigh Valley Hospice provides specialized
services designed particularly for cancer patients by
a professional staff, many of whom are registered
nurses certified in oncology. An inpatient hospice
unit within LVH began operation in 1996 in
response to community need. The unit is designed
to provide care in a home-like setting and empha-
sizes symptom relief through medical and nursing
care, in addition to supportive care for families.
Oncer Committee Report
During 1996, the Cancer Committee began a process of restructure and reorganization with the
approval and adoption of the Commission on Cancer's "Cancer Program Standards." As a result, the
purpose, duties and membership of the Cancer Committee were amended to assure:
• the program and services of the John and Dorothy Morgan Cancer Center
and Lehigh Valley Hospital meet, at a minimum, the standards of the
Commission on Cancer;
• active contribution by the medical staff to advance the mission of LVH's
cancer program;
• the activities and duties of the Cancer Committee and the
Morgan Cancer Center are integrated with each other.
Structure
••
Significant changes in the content of the cancer
program and role of the Cancer Committee were
included in the newly adopted standards. To accom-
modate these changes, the Cancer Committee
adopted a new cancer program structure with a
focus on disease management programs. As a result,
medical staff input into cancer program design and
management is assured through participation in the
Executive Committee, Cancer Committee and
Disease Oriented Programs. Changes to the
Committee's purpose, duties and membership were
made to further accommodate requirements of the
Cancer Program Standards. Restructuring will
continue into 1997.
Services/Programs
The Cancer Committee developed a physician
staging system for primary cancers for all sites for
which there are AJCC staging criteria available.
This system will provide staging documentation on
patients' medical records and will be helpful in
developing treatment plans.
The committee also approved the management
guidelines of colon/rectal, breast, prostate,
pancreatic and thyroid cancers. Reports of confor-
Robert Riether, M.D.
Chairman
mance monitoring for each site were reviewed,
plans of action to correct areas of deficiency and
promote areas of strength were developed and
returned to the Oncology Clinical Indicators
Program for implementation.
Quality Improvement Program
The Cancer Committee monitored the quality
of data abstracted by the Tumor Registry. Through
the electronic edit check program, 2,922 abstracts
were validated in 1996 with a 2.7 percent average
error rate, which was within the acceptable range.
The committee also reviewed Tumor Registry
edit checks and field edits of National Cancer Data
Base data submission for 1989 and 1994 analytic
cases. For 1989, the registry submitted 1,359 cases
with a case error rate of 3.75 percent and 57,078
fields with an error rate of 0.08 percent. For 1994,
the registry submitted 1,570 cases with a case error
rate of 5.92 percent and 65,940 fields with an error
rate of 0.14 percent. The committee noted that the
majority of errors involved surgery codes and
staging by site.
The committee recommended a detailed review
of the AJCC staging rules, which also was
performed in 1996.
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Incidence by County of County of Residence 1992 1993 1994 1995 1996
Allegheny 0 2 0 0 0
Residence-Analytic Cases Berks 79 91 86 83 83
Bucks 28 22 45 19 25
Carbon 112 105 85 91 78
The changing trend in the incidence of new cancer cases Centre 2 1 1 0 0
initially diagnosed and/or treated at Lehigh Valley Hospital, Chester 0 0 0 0 1
first noted among 1995 cases, continues in accession year Clarion 0 0 0 1 0
1996. Total number of analytic cases has decreased particu- Clinton 0 0 0 0 1
larly in cancers occurring in the breast, prostate and lymph Columbia 1 1 0 0 0
nodes. A corresponding volume increase in the number of Cumberland 0 3 0 1 0
cancer cases diagnosed and treated in a staff physicians office Delaware 0 0 2 0 0
is observed. These cases will be accessioned into the registry Fayette 0 1 0 0 0
as analytic cases at a future date, which will be determined by Jefferson 1 0 0 0 0
the Commission on Cancer.
Lackawanna 3 0 4 4 5
Lancaster 0 2 4 0 1
At the same time, a decrease in the number of non-analytic Lebanon 0 0 2 1 0
cancer cases is noted in the accompanying table. Lehigh 1108 1148 1005 1020 983
Luzerne 34 30 38 44 44
Mercer 0 0 2 2 0
Monroe 42 46 30 40 64
Montgomery 25 33 36 38 35
Northampton 182 161 150 177 163
orthumberland 0 0 1 0 0
Philadelphia 1 0 1 0 0
Pike 4 3 3 0 3
Schuylkill 43 38 42 36 39
Susquehanna 0 0 0 0 1
Susquehanna Wayne 1 1 3 0 2
Westmoreland 1 0 0 0 0
Wayne Wyoming 0 0 1 0 0
York 0 1 1 0 0
Wyoming Out of State 44 23 28 66 40
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1996 New Accessions by Primary Site
Analytic Cases
Head and Neck (N=30) Male Female Male Genital Organs (N=208) Male Female
Ton e 4 0 Penis 1 0
Gum 1 2 Prostate 203 0
Mouth 4 1 Testis 4 0
Palate 1 0 Subtotal 208 0
1 Saliva Glands 0 1Tonsil 0 1 Urinary Tract Organs (N=106) Male Female
.f Nasopharynx 1 1 Kidne 20 7Maxilla Sinus 0 2 Renal Pelvis 2 0
La nx 8 3 UreterlUrethra 1 1
Subtotal 19 11 Bladder 46 29
Subtotal 69 37
Digestive Organs (N=290) Male Female
Eso ha s 14 4 Central Nervous System (N=54) Male Female
Stomach 13 5 Menin es 9 7
Small Intestine 4 2 Brain 17 14
Colon & Rectum 112 94 Other Ill-defined CNS Sites 5 2
Anus & Anal Canal 2 1 Subtotal 31 23
Liver & Intrahe atic Bile Ducts 5 1
Gallbladder & Extrahe atic Bile Ducts 2 7 Endocrine Glands (N=45) Male Female
Pancreas 12 12 Th roid 7 25
Subtotal 164 126 Other Endocrine Glands 9 4
Subtotal 16 29
Respiratory Organs (N=196) Male Female
Bronchus & Lun 111 75 Skin (N=96) Male Female
Heart, Mediastinum & Pleura 8 2 Reportable Sites and Deeply
Subtotal 119 77 Invasive Basal & Squamous
Cell Tumor and Melanomas 59 37
Breast (N=256) Male Female Subtotal 59 37
Breast 3 253
Subtotal 3 253 Other Sites (N= 133) Male Female
Female Genital Organs (N=154)
Hematopoietic and
Male Female Reticuloendothelial S stems 16 15
Cervix 0 33 Soft Tissue 4 6
Endometrium 0 64 Lymph Nodes 25 17
Ova 0 41 Other Ill-defined Sites 4 2
Vulva 0 11 Prima Unknown 20 24•• Va ina 0 Subtotal1 69 64
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Mark Gittleman, M.D., Chair,
Breast Disease Management Group
Breast cancer accounted for 16.3 percent of new cases detected at Lehigh
Valley Hospital (LVH) in 1996. Fifty-five percent of those cases occurred in
women 60 years of age or older. A comparison of AJCC stage of disease at
diagnosis between LVH and the National Cancer Data Base (NCDB) revealed
that a greater percentage of early stage disease (AJCC Stage Group 0 and 1)
cases were detected at LVH than NCDB. At LVH a greater percentage of
cases were clinically and/or pathologically staged, thus enhancing data analysis.
Comparison of the use of breast conserving treatment (i.e. lumpectomy/ partial
mastectomy with or without axillary nodal dissection) revealed greater use of
this approach at LVH than other NCDB reporting hospitals.
















COMPARISON OF AJCC STAGE AT DIAGNOSIS
v
50%
COMPARISON OF BREAST CONSERVING TREATMENT, AJCC STAGES 0, 1 AND 2
I
• LVH 1996 Cases
NCDB 1992 Cases
30% 40% 60%50%
;b 1996 BREAST ANALYTIC CASES
I
Initial Treatment by AJCC Stage
Stage Stage Stage Stage Stage Stage Stage Stage.•. Treatment 0 1 2A 2B 3A 3B 4 Unknown Total
Surgery 18 48 34 13 1 6 2 1 123
Surgery + RT 12 40 10 11 1 2 1 0 77
Surgery + Systemic 0 2 3 2 1 1 1 0 10
RT + Systemic 0 0 0 0 0 0 4 0 4
Surgery + Systemic + RT 0 12 5 9 3 1 3 1 34
Systemic 0 1 0 0 0 0 0 0 1
RT 0 1 0 0 0 1 2 0 4
None 0 1 0 0 0 0 1 1 3
TOTAL 30 105 52 35 6 11 14 3 256
'Systemic includes Chemotherapy & Hormone Therapy
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COMPARISON OF AJCC STAGE AT DIAGNOSIS
24 CasesStage 0
3.350 Cases ~
Stage 1 33 Cases8.182 Cases 1
S 2 59 Cases
tage 11.642 Cases i
Stage 3 43 Cases '19,477 Cases
Stage 4 30 Cases • LVH 1996 Cases7.598 Cases - NCDB 1992 Cases
0% 10% 20% 30% 40% 50%
Colon/Rectal
Robert Riether, M.D., Chair,
Colon/Rectal Disease Management Group
While the incidence of colorectal cancer has fallen substantially in recent
years according to the American Cancer Society (1996), cancer of this
site has accounted for an average 13 percent of new cancer cases at Lehigh
Valley Hospital (LVH). The distribution of early and advanced stages of
disease is similar among LVH and National Cancer Data Base (NCDB)
cases. Of interest are differences in patient management among the two
populations. The majority of LVH patients are treated by two approaches:
surgery as monomodal therapy and a combined approach using surgery and
radiation therapy. With NCDB cases, the combined approach most often
used was surgery and chemotherapy.
COMPARISON OF PATIENT MANAGEMENT
"
Surgery
Surgery + RT -
Surgery + Cherno I






















• LVH 1996 Cases
NCDB 1992 Cases
30% 40% 50% 60% 70% 80% 90% 100%
1996 COLON/RECTUM ANALYTIC CASES
Initial Treatment ~yA.JCC Stage
Stage Stage Stage Stage Stage Stage Non- Stage
Treatment 0 1 2 3 4 Existing Unknown Total
Surgery 22 30 47 35 20 . 2 11 167
Surgery + RT 0 3 6 5 0 0 1 15
Surgery + Cherno 0 0 0 1 1 0 0 2
Surgery + Cherno + RT 0 0 4 2 0 0 2 8
RT 0 0 0 0 3 0 1 4
None 2 0 2 0 6 0 0 10





Richard Lieberman, M.D., and Edward Mullin, M.D., Chairs,
Genitourinary Disease Management Group
Prostate cancer comprises 13 percent of 1996 cancer cases at Lehigh Valley
Hospital (LVH) and represents a decrease in the analytic case load from
the prior five years. Fifty percent of cases were detected in men 70 years of
age and older. A greater percent of cases at LVH, when compared to cases
analyzed by National Cancer Data Base (NCDB), were diagnosed at an
early stage of disease (AJCC Stage Group 0, 1 and 2). Patient management
strategies were similar among LVH and NCDB cases. At LVH, a decrease
in the percent of cases treated by observation and an increase in the use of
definitive radiation therapy was noted from the previous year.
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COMPARISON OF PATIENT MANAGEMENT
Surgery" J
RT ,
Observation • LVH 1996 Cases
NCDB 1992 Cases- -
0% 50%10% 20% 30% 40%
"Surgeryeprostatectomy
1996 PROSTATE ANALYTIC CASES
Initial Treatment by AJCC Stage
Stage Stage Stage Stage Stage Stage
I
Treatment 0 1 2 3 4 Unknown Total
Surgery 1 8 40 13 2 0 64
,.•. Surgery + RT 0 0 4 4 2 0 10
Sur 'ery + Hormones 0 1 1 0 0 1 3
Hormones 0 1 1 0 2 0 4
RT 3 46 13 2 0 2 66
RT + Hormones 0 10 6 3 3 0 22
Other 1 0 0 0 0 0 1
Observation 8 19 4 0 1 1 33




Raymond Singer, M.D., Chair,
Pulmonary Disease Management Group
The number of new cases of lung cancer at Lehigh Valley Hospital
(LVH) continues to demonstrate a gradual increase over the past five
years. Similar AJCC stage distributions exist among LVH and National
Cancer Data Base (NCDB) cases. Although similar management
strategies are seen in both patient populations among all tumor
histologies at LVH, slightly greater use is made of surgery and radiation
therapy as individual definitive therapies.
















COMPARISON OF AJCC STAGE AT DIAGNOSIS
S 0 1 Casetage 335 Cases
S 1 41 Cases 1 ••••••••• 11Itage 15.725 Cases ' .. ' .;>;;"'0,.j
S 2 3 Cases I ---.,tage 4.804 Cases ---'
Stage 3 58 Cases 1 ••••••••.... <11I11I>••••• 11,
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Surgery + RT . ....::::J
RT + Chemo I
Other ...: • LVH1996 Cases
NCDB1992 Cases
None
0% 10% 20% 30% 40% 50%
1996 LUNG ANALYTIC CASES
Initial Treatment by AJCC Stage
Stage Stage Stage Stage Stage Stage Non- Stage Stage
Treatment 1 2 3A 3B 4 Existing Unknown DC Total
Surgery 30 1 1 1 1 2 0 0 36
Surgery + RT 1 1 9 0 4 0 0 0 15
Chemo + RT 2 0 4 6 12 0 3 0 27
Surgery + Chemo + RT 0 0 0 0 2 0 0 0 2
Chemo 0 0 0 1 7 0 0 0 8
RT 5 1 10 14 22 0 8 0 60
Other 0 0 0 1 1 0 0 0 2
None 3 0 5 6 15 0 6 1 36
TOTAL 41 3 29 29 64 2 17 1 186
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Skin
Alan H. Schragger, M.D., Chair,
Skin Disease Management Group
Skin cancer was detected in 6.2 percent of 1996 analytic cancer cases at
Lehigh Valley Hospital (LVH). People 60 years of age and older were
diagnosed with 61.0 percent of the skin cancers at LVH. Forty-eight
percent of cases were found at AJCC Stage Groups 0 and 1. Surgery
alone was the treatment of choice for nearly all cases. This figure is

















COMPARISON OF AJCC STAGE AT DIAGNOSIS
Stage 0 13 Cases
Stage 1 43 Cases
Stage 2 15 Cases
Stage 3 o Cases
Stage 4 4 Cases-
0% 10%
• LVH 1996 Cases
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ACS 1996 Cases
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1996 SKIN ANALYTIC CASES
Initial Treatment by Stage
Stage Stage Stage Stage Stage Stage Non- Stage
Treatment 0 1 2 3 4 Existing Unknown Total
12 42 13 0 1 14 3 85
0 0 0 0 2 0 0 2
0 0 1 0 0 0 0 1
RT 0 0 1 0 1 1 0 3
None 1 1 0 0 0 2 1 5
TOTAL 13 43 15 0 4 17 4 96
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Patient Care Evaluation: Thyroid Cancer
George W. Hartzell, Jr., M.D.
Analytic thyroid cancer cases (accession years 1985 through 1990)
were evaluated. The 102 thyroid cases were compared with cases
in the National Cancer Data Base (NCDB) along these variables:
age at diagnosis, percent of cases by diagnostic year and histologic
subgroup, stage of disease and type of surgery. Survival rates were
calculated and presented in graphic form.
The purpose of the comparison was to detect significant
similarities and differences that might be addressed in the form
of guidelines for treatment.
A comparison of histologic subgroup and age at diagnosis was
made between Lehigh Valley Hospital (LVH) and NCDB
(Figures 1 and 2). This comparison revealed a difference in the
incidence of medullary and undifferentiated carcinomas in the
two populations.
In examining histologic differences by best stage of disease
(Tables 1.1 and 1.2) a lower percentage ofLVH patients with
Stage 3 disease had papillary and follicular carcinoma than found
among NCDB cases.
Treatment similarities among both populations was demonstrated
in Tables 2.1 and 2.2. In both groups, lobectomy with isthmu-
sectomy was the surgical procedure most frequently performed.
Among LVH patients, a higher percentage with follicular thyroid
cancer were treated with surgery alone in comparison to
NCDB cases.
Five-year survival analysis was performed by the relative method
according to stage of disease at diagnosis. LVH findings (Tables
3.1 and 3.2) were similar to NCDB with a slightly lower rate of
survival among patients with Stage 4 papillary cancer.
Although the findings of this evaluation demonstrate many
similarities between LVH and NCDB thyroid cancer incidence
and management, it was determined guidelines for care should
address indications for each surgical procedure, as well as indica-
tions for a combined modality approach to care.
As a result of this study, guidelines for care were developed and
implemented on October 1, 1996. Guidelines include recommen-
dations for treatment according to stage of disease and histology.
The effectiveness of these guidelines will be evaluated in 1997.
Figure 1. LVH77Jyroid Data. Years 1985 to 1990
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Figure 2. NCDB ThY1"oidData. J-em's 198611987, 1992
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Thyroid Cancer
I PERCENTAGE OF THYROID CASES BY STAGE
Table 1.1. LVH Data.
Histology Stage Stage Stage Stage Unable Total
1 2 3 4 to Stage Cases
Papillary 69.0 19.0 8.3 2.4 1.2 84





I PERCENTAGE OF THYROID CASES BY STAGE
Table 1.2. NCDB Data
Histology Stage Stage Stage Stage Unable Total
1 2 3 4 to Stage Cases
Papillary 62.1 17.5 16.7 3.7 2949
Follicular 51.8 28.6 13.2 6.4 1630
Medullary 15.1 35.2 35.9 13.8 159
Undifferentiated 100.0 33
I PERCENTAGE OF THYROID CANCER CASES BY SURGERy/HISTOLOGY
Iltble 2.1. LVH Dnta.
Total
Total Total Thyroidectomy
Lobectomy Thyroidectomy Thyroidectomy with Radical
Histology None with without Lymph with Lymph or Modified Total
Unknown Isthmusectomy Nodes Nodes Lymph Nodes Other Cases
•• Papillary 1.2 36.9 28.6 16.7 14.3 2.4 84




I PERCENTAGE OF THYROID CANCER CASES BY SURGERy/HISTOLOGY
TobIe 2.2. NCDB Data.
Total
Total Total Thyroidectomy
i Lobectomy Thyroidectomy Thyroidectomy with Radical
II
Histology None with without Lymph with Lymph or Modified Total
Unknown Isthmusectomy Nodes Nodes Lymph Nodes Other Cases
I'
Papillary 6.7 34.2 28.3 18.4 7.6 4.8 3512
Follicular 5.3 41.6 34.5 10.3 4.7 3.6 1956
Medullary 9.1 19.9 24.2 17.2 25.3 4.3 186




SURVIVAL COMPARISON OF PAPILLARY CARCINOMA
Table 3.1. LVH Data: 'Relative 5-Yea,' Suruiual Rates by Best AJCC Stage, N=84
Interval Stage 1 Stage 2 Stage 3 Stage 4 Stage Unknown
Year % % % % %
0 100.0 100.0 100.0 100.0 100.0
1 100.0 100.0 87.0 100.0 100.0
2 100.0 100.0 87.0 51.5 100.0
3 98.8 100.0 69.6 51.5 100.0
4 98.8 100.0 69.6 51.5 100.0
5 86.8 95.1 69.6 51.5 100.0
Relative 5-year
Survival Rate 96.86% 95.16% 69.67% 51.58% 100.00%
Average Age at
Diagnosis 43.6 56.94 59 65 52
'Relative Survival Rate is based on 1980 Standard Year for Expected Rates.
SURVIVAL COMPARISON OF PAPILLARY CARCINOMA
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